Viloxazine Explained

Verifiedfields:changed
Watchedfields:changed
Verifiedrevid:470630208
Width:175
Width2:175
Chirality:Racemic mixture
Tradename:Qelbree, others
Dailymedid:Viloxazine
Routes Of Administration:By mouth
Class:Antidepressant
Norepinephrine reuptake inhibitor
Atc Prefix:N06
Atc Suffix:AX09
Legal Us:Rx-only
Protein Bound:76–82%
Metabolism:Hydroxylation (CYP2D6), glucuronidation (UGT1A9, UGT2B15)
Metabolites:5-Hydroxyviloxazine glucuronide
Elimination Half-Life:

2–5 hours[1]
: 7.02 ± 4.74 hours

Excretion:Urine (~90%), feces (<1%)[2]
Index2 Label:HCl
Cas Number:46817-91-8
Cas Number2:35604-67-2
Pubchem:5666
Drugbank:DB09185
Drugbank2:DBSALT001262
Chemspiderid:5464
Chemspiderid2:64514
Unii:5I5Y2789ZF
Unii2:OQW30I1332
Kegg:D08673
Kegg2:D02572
Chebi:94405
Chembl:306700
Chembl2:2106483
Synonyms:ICI-58834; SPN-812; SPN-809
Iupac Name:(RS)-2-[(2-ethoxyphenoxy)methyl]morpholine[3]
C:13
H:19
N:1
O:3
Smiles:CCOC1=CC=CC=C1OCC1CNCCO1
Smiles2:Cl.CCOC1=CC=CC=C1OCC1CNCCO1
Stdinchi:1S/C13H19NO3/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11/h3-6,11,14H,2,7-10H2,1H3
Stdinchi2:1S/C13H19NO3.ClH/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11;/h3-6,11,14H,2,7-10H2,1H3;1H
Stdinchikey:YWPHCCPCQOJSGZ-UHFFFAOYSA-N
Stdinchikey2:HJOCKFVCMLCPTP-UHFFFAOYSA-N

Viloxazine, sold under the brand name Qelbree among others, is a selective norepinephrine reuptake inhibitor medication which is used in the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.[4] [5] It was marketed for almost 30years as an antidepressant for the treatment of depression before being discontinued and subsequently repurposed as a treatment for ADHD.[6] Viloxazine is taken orally. It was used as an antidepressant in an immediate-release form and is used in ADHD in an extended-release form, latterly with comparable effectiveness to atomoxetine and methylphenidate.[7]

Side effects of viloxazine include insomnia, headache, somnolence, fatigue, nausea, vomiting, decreased appetite, dry mouth, constipation, irritability, increased heart rate, and increased blood pressure. Rarely, the medication may cause suicidal thoughts and behaviors. It can also activate mania or hypomania in people with bipolar disorder. Viloxazine acts as a selective norepinephrine reuptake inhibitor (NRI). The immediate-release form has an elimination half-life of 2.5hours while the half-life of the extended-release form is 7hours.

Viloxazine was first described by 1972 and was marketed as an antidepressant in Europe in 1974. It was not marketed in the United States at this time. The medication was discontinued in 2002 for commercial reasons. However, it was repurposed for the treatment of ADHD and was reintroduced, in the United States, in April 2021.[8] [9] Viloxazine is a non-stimulant medication; it has no known misuse liability and is not a controlled substance.

Medical uses

Attention deficit hyperactivity disorder

Viloxazine is indicated to treat attention deficit hyperactivity disorder (ADHD) in children age 6 to 12years, adolescents age 13 to 17years, and adults.

Analyses of clinical trial data suggest that viloxazine produces moderate reductions in symptoms; it is about as effective as atomoxetine and methylphenidate but with fewer side effects.[10] [11]

Depression

Viloxazine was previously marketed as an antidepressant for the treatment of major depressive disorder. It was considered to be effective in mild to moderate as well as severe depression with or without co-morbid symptoms. The typical dose range for depression was 100 to 400mg per day in divided doses administered generally two to three times per day.

Available forms

Viloxazine is available for ADHD in the form of 100, 150, and 200 mg extended-release capsules. These capsules can be opened and sprinkled into food for easier administration.

Side effects

The most common side effects include drowsiness, headache, loss of appetite. Psychiatric side effects occur in about 20% of cases; the most common of these is irritability (>5%).[12] Other common side effects include nausea, vomiting, epigastric pain, insomnia,[6] and increased libido.[13] Incidence of some side effects, including headache and drowsiness, appear to be dose-dependent.[14] In the treatment of depression, viloxazine is more tolerable than tricyclic antidepressants such as imipramine and amitryptiline.[6]

There were three cases of seizure worldwide, and most animal studies [and clinical trials that included [[epilepsy]] patients] indicated the presence of anticonvulsant properties, so viloxazine is not completely contraindicated in patients with epilepsy.[15]

Interactions

Viloxazine increased plasma levels of phenytoin by an average of 37%.[16] It also was known to significantly increase plasma levels of theophylline and decrease its clearance from the body,[17] sometimes resulting in accidental overdose of theophylline.[18]

Pharmacology

Pharmacodynamics

Viloxazine acts as a selective norepinephrine reuptake inhibitor and this is believed to be responsible for its therapeutic effectiveness in the treatment of conditions like ADHD and depression. The affinities (KD) of viloxazine at the human monoamine transporters are 155 to 630 nM for the norepinephrine transporter (NET), 17,300 nM for the serotonin transporter (SERT), and >100,000 nM for the dopamine transporter (DAT).[19] Viloxazine has negligible affinity for a variety of assessed receptors, including the serotonin 5-HT1A and 5-HT2A receptors, the dopamine D2 receptor, the α1- and α2-adrenergic receptors, the histamine H1 receptor, and the muscarinic acetylcholine receptors (all >10,000 nM).[20] [21]

More recent research has found that the pharmacodynamics of viloxazine may be more complex than previously assumed.[22] In 2020, viloxazine was reported to have significant affinity for the serotonin 5-HT2B and 5-HT2C receptors (Ki = 3,900 nM and 6,400 nM) and to act as an antagonist and agonist of these receptors, respectively. It also showed weak antagonistic activity at the serotonin 5-HT7 receptor and the α1B- and β2-adrenergic receptors. These actions, although relatively weak, might be involved in its effects and possibly its therapeutic effectiveness in the treatment of ADHD.

Pharmacokinetics

Absorption

The bioavailability of extended-release viloxazine relative to an instant-release formulation was about 88%. Peak and levels of extended-release viloxazine are proportional over a dosage range of 100 to 400 mg once daily. The time to peak levels is 5 hours with a range of 3 to 9 hours after a single 200 mg dose. A high-fat meal modestly decreases levels of viloxazine and delays the time to peak by about 2 hours. Steady-state levels of viloxazine are reached after 2 days of once-daily administration and no accumulation occurs. Levels of viloxazine are approximately 40 to 50% higher in children age 6 to 11 years compared to children age 12 to 17 years.

Distribution

The plasma protein binding of viloxazine is 76 to 82% over a concentration range of 0.5 to 10 μg/mL.

Metabolism

The metabolism of viloxazine is primarily via the cytochrome P450 enzyme CYP2D6 and the UDP-glucuronosyltransferases UGT1A9 and UGT2B15. The major metabolite of viloxazine is 5-hydroxyviloxazine glucuronide. Viloxazine levels are slightly higher in CYP2D6 poor metabolizers relative to CYP2D6 extensive metabolizers.

Elimination

The elimination of viloxazine is mainly renal. Approximately 90% of the dose is excreted in urine within 24 hours and less than 1% of the dose is recovered in feces.

The elimination half-life of instant-release viloxazine is 2 to 5 hours (2–3 hours in the most reliable studies) and the half-life of extended-release viloxazine is 7.02 ± 4.74 hours.

Chemistry

Viloxazine is a racemic compound with two stereoisomers, the (S)-(–)-isomer being five times as pharmacologically active as the (R)-(+)-isomer.[23]

History

Viloxazine was discovered by scientists at Imperial Chemical Industries when they recognized that some beta blockers inhibited serotonin reuptake inhibitor activity in the brain at high doses. To improve the ability of their compounds to cross the blood brain barrier, they changed the ethanolamine side chain of beta blockers to a morpholine ring, leading to the synthesis of viloxazine.[24] [25] It was first described in the scientific literature as early as 1972.[26]

The medication was first marketed in 1974.[27] Viloxazine was not approved for medical use by the FDA.[28] In 1984, the FDA granted the medication an orphan designation for treatment of cataplexy and narcolepsy with the tentative brand name Catatrol.[29] For unknown reasons however, it was never approved or introduced for these uses in the United States. Viloxazine was withdrawn from markets worldwide in 2002 for commercial reasons unrelated to efficacy or safety.[24]

As of 2015, Supernus Pharmaceuticals was developing extended release formulations of viloxazine as a treatment for ADHD and major depressive disorder under the names SPN-809 and SPN-812.[30] [31] Viloxazine was approved for the treatment of ADHD in the United States in April 2021.

The benefit of viloxazine was evaluated in three clinical studies, including two in children (ages 6 to 11 years) and one in adolescents (ages 12 to 17 years) with ADHD. In each study, pediatric participants were randomly assigned to receive one of two doses of viloxazine or placebo once daily for 6 to 8 weeks. None of the participants, their parent(s)/caregiver(s), the study sponsor, or the study doctors knew which treatment the participant received during the study. The severity of ADHD symptoms observed at the last week of treatment was significantly greater in participants who received placebo compared with participants who received viloxazine. The severity of ADHD symptoms was assessed using the Attention-Deficit Hyperactivity Disorder Rating Scale 5th Edition (ADHD-RS-5). A fourth study provided information about the safety of viloxazine in adolescents 12 to 17 years of age with ADHD. The FDA approved viloxazine based on evidence from several clinical trial(s) of 1289 participants with attention deficit hyperactivity disorder (ADHD). The trials were conducted at 59 sites in the United States.[32]

Society and culture

Brand names

Viloxazine has been marketed under the brand names Emovit, Qelbree, Vicilan, Viloxazin, Viloxazina, Viloxazinum, Vivalan, and Vivarint.[33]

Research

Viloxazine has undergone two randomized controlled trials for nocturnal enuresis (bedwetting) in children, both of those times versus imipramine.[34] [35] By 1990, it was seen as a less cardiotoxic alternative to imipramine, and to be especially effective in heavy sleepers.[36]

In narcolepsy, viloxazine has been shown to suppress auxiliary symptoms such as cataplexy and also abnormal sleep-onset REM[37] without significantly improving daytime somnolence.[38] In a cross-over trial (56 participants) viloxazine significantly reduced EDS and cataplexy.[39]

Viloxazine has also been studied for the treatment of alcoholism, with some success.[40]

Viloxazine did not demonstrate efficacy in a double-blind randomized controlled trial versus amisulpride in the treatment of dysthymia.[41]

Notes and References

  1. Pinder RM, Brogden RN, Speight TM, Avery GS . Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness . Drugs . 13 . 6 . 401–421 . June 1977 . 324751 . 10.2165/00003495-197713060-00001 . 44804763 .
  2. Case DE, Reeves PR . The disposition and metabolism of I.C.I. 58,834 (viloxazine) in humans . Xenobiotica; the Fate of Foreign Compounds in Biological Systems . 5 . 2 . 113–129 . February 1975 . 1154799 . 10.3109/00498257509056097 .
  3. Web site: SID 180462 . PubChem Substance Summary . U.S. National Library of Medicine . 5 November 2005 . 14 June 2013 . https://web.archive.org/web/20130614150110/http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=180462 . live .
  4. Web site: Qelbree- viloxazine hydrochloride capsule, extended release . DailyMed . 3 May 2022 . 28 October 2022 . https://web.archive.org/web/20221028144257/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aedf408d-0f84-418d-9416-7c39ddb0d29a . live .
  5. Cutler AJ, Mattingly GW, Jain R, O'Neal W . Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents . CNS Spectrums . 27 . 2 . 199–207 . April 2022 . 33121553 . 10.1017/S1092852920001984 . free .
  6. Findling RL, Candler SA, Nasser AF, Schwabe S, Yu C, Garcia-Olivares J, O'Neal W, Newcorn JH . 6 . Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status . CNS Drugs . 35 . 6 . 643–653 . June 2021 . 34003459 . 8219567 . 10.1007/s40263-021-00825-w .
  7. Schein J, Cloutier M, Gauthier-Loiselle M, Catillon M, Xu C, Chan D, Childress A . Assessment of centanafadine in adults with attention-deficit/hyperactivity disorder: A matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-release . Journal of Managed Care & Specialty Pharmacy . 30 . 6 . 528–540 . June 2024 . 38824626 . 10.18553/jmcp.2024.30.6.528 . 11145007 .
  8. Web site: Qelbree: FDA-Approved Drugs . U.S. Food and Drug Administration (FDA) . 2 April 2021 . 2 April 2021 . https://web.archive.org/web/20210402190140/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211964 . live .
  9. Supernus Announces FDA Approval of Qelbree (SPN-812) for the Treatment of ADHD . Supernus Pharmaceuticals . 2 April 2021 . 3 April 2021 . 6 April 2021 . https://web.archive.org/web/20210406133754/https://ir.supernus.com/news-releases/news-release-details/supernus-announces-fda-approval-qelbreetm-spn-812-treatment-adhd . live .
  10. Faraone SV, Gomeni R, Hull JT, Busse GD, Melyan Z, O'Neal W, Rubin J, Nasser A . 6 . Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials . Psychiatry Research . 296 . 113664 . February 2021 . 33418457 . 10.1016/j.psychres.2020.113664 . 230716405 . free .
  11. Bushe C, Day K, Reed V, Karlsdotter K, Berggren L, Pitcher A, Televantou F, Haynes V . 6 . A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients . Journal of Psychopharmacology . 30 . 5 . 444–458 . May 2016 . 27005307 . 10.1177/0269881116636105 . 104938 .
  12. Pozzi M, Bertella S, Gatti E, Peeters GG, Carnovale C, Zambrano S, Nobile M . Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD) . Expert Opinion on Emerging Drugs . 25 . 4 . 395–407 . December 2020 . 32938246 . 10.1080/14728214.2020.1820481 . 221768208 . free . 2434/851076 . free .
  13. Chebili S, Abaoub A, Mezouane B, Le Goff JF . [Antidepressants and sexual stimulation: the correlation] . fr . L'Encephale . 24 . 3 . 180–184 . 1998 . 9696909 . Antidepressants and sexual stimulation: the correlation .
  14. Poznanski AJ, Akinyemi E . Recent Advances in Psychopharmacology . Advances in Psychiatry and Behavioral Health . September 2022 . 2 . 1 . 253–266 . 10.1016/j.ypsc.2022.03.009. 252258910 .
  15. Edwards JG, Glen-Bott M . Does viloxazine have epileptogenic properties? . Journal of Neurology, Neurosurgery, and Psychiatry . 47 . 9 . 960–964 . September 1984 . 6434699 . 1027998 . 10.1136/jnnp.47.9.960 .
  16. Pisani F, Fazio A, Artesi C, Russo M, Trio R, Oteri G, Perucca E, Di Perri R . 6 . Elevation of plasma phenytoin by viloxazine in epileptic patients: a clinically significant drug interaction . Journal of Neurology, Neurosurgery, and Psychiatry . 55 . 2 . 126–127 . February 1992 . 1538217 . 488975 . 10.1136/jnnp.55.2.126 .
  17. Perault MC, Griesemann E, Bouquet S, Lavoisy J, Vandel B . A study of the interaction of viloxazine with theophylline . Therapeutic Drug Monitoring . 11 . 5 . 520–522 . September 1989 . 2815226 . 10.1097/00007691-198909000-00005 .
  18. Laaban JP, Dupeyron JP, Lafay M, Sofeir M, Rochemaure J, Fabiani P . Theophylline intoxication following viloxazine induced decrease in clearance . European Journal of Clinical Pharmacology . 30 . 3 . 351–353 . 1986 . 3732375 . 10.1007/BF00541543 . 10114046 . free .
  19. Tatsumi M, Groshan K, Blakely RD, Richelson E . Pharmacological profile of antidepressants and related compounds at human monoamine transporters . European Journal of Pharmacology . 340 . 2–3 . 249–258 . December 1997 . 9537821 . 10.1016/s0014-2999(97)01393-9 .
  20. Richelson E, Nelson A . Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro . The Journal of Pharmacology and Experimental Therapeutics . 230 . 1 . 94–102 . July 1984 . 6086881 .
  21. Wander TJ, Nelson A, Okazaki H, Richelson E . Antagonism by antidepressants of serotonin S1 and S2 receptors of normal human brain in vitro . European Journal of Pharmacology . 132 . 2–3 . 115–121 . December 1986 . 3816971 . 10.1016/0014-2999(86)90596-0 .
  22. Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V . New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties . Journal of Experimental Pharmacology . 12 . 285–300 . 2020 . 32943948 . 7473988 . 10.2147/JEP.S256586 . free .
  23. Danchev ND, Rozhanets VV, Zhmurenko LA, Glozman OM, Zagorevskiĭ VA . [Behavioral and radioreceptor analysis of viloxazine stereoisomers] . ru . Biulleten' Eksperimental'noi Biologii I Meditsiny . 97 . 5 . 576–578 . May 1984 . 6326891 . Behavioral and radioreceptor analysis of viloxazine stereoisomers .
  24. Book: Williams DA . Chapter 18: Antidepressants. . Foye's Principles of Medicinal Chemistry . Lemke TL, Williams DA . Lippincott Williams & Wilkins . 2012 . 9781609133450.
  25. Book: Wermuth CG . Chapter 1: Analogs as a Means of Discovering New Drugs. . Analogue-based Drug Discovery. . Fischer J, Ganellin CR . John Wiley & Sons . 2006 . 978352760749-5.
  26. Mallion KB, Todd AH, Turner RW, Bainbridge JG, Greenwood DT, Madinaveitia J, Somerville AR, Whittle BA . 6 . 2-(2-ethoxyphenoxymethyl)tetrahydro-1,4-oxazine hydrochloride, a potential psychotropic agent . Nature . 238 . 5360 . 157–158 . July 1972 . 4558457 . 10.1038/238157a0 . 4268001 . 1972Natur.238..157M .
  27. Book: Olivier B, Soudijn W, van Wijngaarden I . Serotonin, dopamine and norepinephrine transporters in the central nervous system and their inhibitors . Progress in Drug Research. Fortschritte der Arzneimittelforschung. Progres des Recherches Pharmaceutiques . 54 . 59–119 . 2000 . 10857386 . 10.1007/978-3-0348-8391-7_3 . 978-3-0348-9546-0 .
  28. Book: Dahmen MM, Lincoln J, Preskorn S . NARI Antidepressants . 816–822 . Encyclopedia of Psychopharmacology . Stolerman IP . Springer-Verlag . Berlin Heidelberg . 2010 . 9783540687061.
  29. Web site: U.S. Food and Drug Administration . Orphan Drug Designations and Approvals: Viloxazine . https://web.archive.org/web/20220625004326/https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=2384 . 2022-06-25 . 1 August 2015 .
  30. Web site: Bloomberg . Supernus profile . https://web.archive.org/web/20180311202516/https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=422832 . 2018-03-11 . 1 August 2015 .
  31. Web site: Supernus . Psychiatry portfolio . https://web.archive.org/web/20160417060946/http://www.supernus.com/psychiatry-portfolio . 2016-04-17 . 1 August 2015 .
  32. Web site: Drug Trials Snapshots: Qelbree . U.S. Food and Drug Administration . 13 March 2023 . 13 March 2023 . 14 March 2023 . https://web.archive.org/web/20230314051311/https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-qelbree . live .
  33. Book: Swiss Pharmaceutical Society . Swiss Pharmaceutical Society . 2000 . Index Nominum 2000: International Drug Directory . Taylor & Francis . 1093– . 978-3-88763-075-1 . 2022-05-03 . 2023-01-14 . https://web.archive.org/web/20230114093413/https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA1093 . live .
  34. Attenburrow AA, Stanley TV, Holland RP . Nocturnal enuresis: a study . The Practitioner . 228 . 1387 . 99–102 . January 1984 . 6364124 .
  35. Yurdakök M, Kinik E, Güvenç H, Bedük Y . Viloxazine versus imipramine in the treatment of enuresis . The Turkish Journal of Pediatrics . 29 . 4 . 227–230 . 1987 . 3332732 .
  36. Libert MH . [The use of viloxazine in the treatment of primary enuresis] . fr . Acta Urologica Belgica . 58 . 1 . 117–122 . 1990 . 2371930 . The use of viloxazine in the treatment of primary enuresis .
  37. Guilleminault C, Mancuso J, Salva MA, Hayes B, Mitler M, Poirier G, Montplaisir J . Viloxazine hydrochloride in narcolepsy: a preliminary report . Sleep . 9 . 1 Pt 2 . 275–279 . 1986 . 3704453 . 10.1093/sleep/9.1.275 . free .
  38. Mitler MM, Hajdukovic R, Erman M, Koziol JA . Narcolepsy . Journal of Clinical Neurophysiology . 7 . 1 . 93–118 . January 1990 . 1968069 . 2254143 . 10.1097/00004691-199001000-00008 .
  39. Vignatelli L, D'Alessandro R, Candelise L . Antidepressant drugs for narcolepsy . The Cochrane Database of Systematic Reviews . 2008 . 1 . CD003724 . January 2008 . 18254030 . 9030766 . 10.1002/14651858.CD003724.pub3 .
  40. Altamura AC, Mauri MC, Girardi T, Panetta B . Alcoholism and depression: a placebo controlled study with viloxazine . International Journal of Clinical Pharmacology Research . 10 . 5 . 293–298 . 1990 . 2079386 .
  41. Mattingly GW, Anderson RH . Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systems . CNS Spectrums . 21 . S1 . 45–59 . December 2016 . 28044946 . 10.1017/S1092852916000808 . 2019-09-24 . live . 24310209 . https://web.archive.org/web/20221013114453/https://digitalcommons.wustl.edu/cgi/viewcontent.cgi?article=6729&context=open_access_pubs . 2022-10-13 .